An update on patient reported outcomes in type 2 inflammation airway disease. Issue 1 (15th February 2023)

• Record Type: Journal Article
• Authors: Pedersen, Christian Korsgaard; Haase, Christiane; Aanaes, Kasper; von Buchwald, Christian; Backer, Vibeke
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 23:Issue 1(2023)
• Page Start: 1
• Page End: 8
• Publication Date: 2023-02-15
• Subjects: global airways disease -- Health-related quality of life -- patient reported outcome measure -- type 2 inflammation; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000873
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: Patient reported outcome measures (PROMs) play an important role in assessing so-called global airway disease caused by type-2 inflammation, not only in terms of patients' perspective on symptoms and treatment/side-effect, but they can also serve as a measure of disease control, and not least as an indicator of possible coexisting comorbidity otherwise unrecognized. The objective of this review was to investigate any newly developed PROMs for global airway disease and to give an overview of the most commonly used PROMs in the management of global airway disease. Recent findings: The Standard Tests for Asthma, Allergic Rhinitis and Rhinosinusitis (STARR-15) is a recently developed PROM aimed to raise clinicians' awareness of coexisting type-2 inflammation disease. Strengths of the STARR-15 is that is quick and symptom-centered, i.e. items are not specifically aimed at a disease the patients might not be aware they have. The STARR-15 has, however, not yet been validated, so details of responsiveness and reproducibility are yet to be determined. Summary: PROMs are a quick and cheap way to assess patient perspectives in global airway disease, and can play an important role in unveiling otherwise overlooked co-existing double disease.